Diet And Ms Treatment by NoMoreVitamins com http://NoMoreVitamins.com - Don't let yourself take pain pills for the rest of your life, please! There's another way no one has told you about, the holistic... By: theHealthFood Guru … Continue reading →

ROCHESTER, Minn. & ARDSLEY, N.Y.--(BUSINESS WIRE)--Mayo Clinic and Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the first patient has been enrolled in the first clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis (MS). This is a Phase 1 clinical trial enrolling people with MS to assess the safety and tolerability of rHIgM22. The study also includes several exploratory efficacy measures. This remyelinating antibody, if successful in clinical trials and approved, would be a novel approach to treating people with chronic neurologic deficits from multiple sclerosis or other similar conditions In MS, a persons own immune system destroys myelin, a substance that insulates nerves and facilitates conduction of nerve impulses that control neurological function such as movement and vision. Progressive damage to myelin causes functional impairment in people with MS. Currently there are no approved therapies that stimulate the repair or regrowth of myelin once it has been damaged. This remyelinating antibody, if successful in clinical trials and approved, would be a novel approach to treating people with chronic neurologic deficits from multiple sclerosis or other similar conditions, said Moses Rodriguez, M.D., a neurologist specializing in MS at the Mayo Clinic, whose team … Continue reading →

Apr. 19, 2013 Research presented Friday aims to find an effective treatment for the two million Americans suffering annually from moderate-to-severe heel pain. John J. Wilson, MD, MS, AMSSM member, presented his research on plantar fasciitis entitled, "Platelet-Rich Plasma for the Treatment of Chronic Plantar Fasciopathy in Adults: A Randomized Controlled Clinical Trial" on Friday, April 19, 2013 at the American Medical Society for Sports Medicine's 22nd Annual Meeting in San Diego, Cal. Dr. Wilson and his colleagues are currently conducting a randomized controlled clinical trial investigating platelet-rich plasma injection for the treatment of chronic plantar fasciitis. Plantar fasciitis is a musculoskeletal disorder affecting the plantar fascia origin and is the most common cause of heel pain in adults. Plantar fasciitis is an important cause of pain and disability among athletes, but also prevalent in the general population, especially sedentary individuals, with previous research estimating two million Americans affected annually. Few studies have assessed PRP as a treatment for plantar fasciitis, and no single study has assessed the degree of correlation between the clinical, biomechanical and ultrasound features of plantar fasciitis in response to therapy. The overall goal of this research is to find an effective treatment for moderate-to-severe chronic … Continue reading →

Newswise SAN DIEGO, CA Research presented Friday aims to find an effective treatment for the two million Americans suffering annually from moderate-to-severe heel pain. John J. Wilson, MD, MS, AMSSM member, presented his research on plantar fasciitis entitled, Platelet-Rich Plasma for the Treatment of Chronic Plantar Fasciopathy in Adults: A Randomized Controlled Clinical Trial on Friday, April 19, 2013 at the American Medical Society for Sports Medicines 22nd Annual Meeting in San Diego, Cal. Dr. Wilson and his colleagues are currently conducting a randomized controlled clinical trial investigating platelet-rich plasma injection for the treatment of chronic plantar fasciitis. Plantar fasciitis is a musculoskeletal disorder affecting the plantar fascia origin and is the most common cause of heel pain in adults. Plantar fasciitis is an important cause of pain and disability among athletes, but also prevalent in the general population, especially sedentary individuals, with previous research estimating two million Americans affected annually. Few studies have assessed PRP as a treatment for plantar fasciitis, and no single study has assessed the degree of correlation between the clinical, biomechanical and ultrasound features of plantar fasciitis in response to therapy. The overall goal of this research is to find an effective treatment for moderate-to-severe … Continue reading →

Global Editor, Kimberly Ha joins expert speakers in an interactive live discussion. Norwood, MA (PRWEB) April 22, 2013 Topics to be discussed incude: Dr. Daniel Kantor is the Medical Director at Neurologique and a member of the health care advisory panel of the MS Foundation. Dr. Kantor has been the principal investigator of several MS studies and a member of the University of California at San Francisco international collaboration studying the genetics of MS. Dr. Kantor has received numerous awards recognizing his four-part focus on academics, teaching, research and administrative excellence for MS. Dr. Samuel Hunter is president of Advanced Neurosciences Institute in Tennessee, a cutting edge subspecialty neurology practice which cooperates with a number of pharmaceutical industry partners to develop and test new therapeutic agents for neurological disease. Dr. Hunter has a broad neurosciences background including pharmacology, developmental neurosciences, molecular neuroscience, neuroimaging, experimental therapy, treatment and research of immune diseases in the nervous system. Currently board-certified in neurology and neuroimaging, Dr. Hunter is also an investigator at Biogen Idec and a consultant for Bayer. Kimberly Ha is an award-winning biopharmaceutical industry journalist and editor. She launched BioPharm Insight's editorial team in 2007. Kimberly is a member of the Galien … Continue reading →